Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries. In addition, it offers AuroSource, a contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for penicillin's, cephalosporins, and non beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Stock data | 2023 | Change |
---|---|---|
Price | $18.52 | N/A |
Market Cap | $10.85B | N/A |
Shares Outstanding | 585.94M | 0.00% |
Employees | 23.45K | N/A |
Shareholder Equity | 268.52B | 9.27% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 0.56 | N/A |
P/S Ratio | 3.70 | N/A |
P/B Ratio | 0.04 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0009 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $2.93B | N/A |
Earnings | $229.68M | N/A |
EPS | 32.90 | N/A |
Earnings Yield | 1.78 | N/A |
Gross Margin | 0.5166 | N/A |
Operating Margin | 0.1031 | N/A |
Net income margin | 0.0783 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $4.75B | N/A |
Total Debt | $629.86M | N/A |
Cash on Hand | $741.56M | N/A |
Debt to Equity | 0.0058 | 27.65% |
Cash to Debt | $1.18 | -15.30% |
Current Ratio | $1.87 | -15.64% |